Charles River Laboratories International, Inc. (CRL) fell 1.90% Tuesday, settling at $272.99 as sellers maintained pressure on the contract research organization. The session's decline added to a pattern of weakness that has persisted through recent trading.
Over the past seven days, CRL has shed 5.39%, and the 30-day period shows a loss of 2.52%, indicating that selling pressure has been building gradually rather than emerging from a single sharp move. The stock's market capitalization stood at $13.28 billion at the close.
The consecutive declines across the one-day, seven-day, and 30-day windows paint a consistent picture of softness for the life sciences services company. No single session has reversed the broader downward drift reflected in the data.
CRL's current price of $272.99 represents the cumulative effect of those losses across multiple measurement periods, leaving the stock down across all three tracked timeframes heading into the following session.
